Aetion, a Datavant Company

New York, NY, United States All United States companies → — Founded 2012

Biotech / Drug Discovery Healthcare Analytics / BI

Cardiology Neurology Oncology

Drug Discovery & Research Population Health Analytics

Acquired (by Datavant) — $212M

Website Claim this company

Products

Aetion Evidence

Aetion, a Datavant Company

Drug Discovery & Research

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value.

Enterprise

See all 1 product →

About Aetion, a Datavant Company

Aetion, a Datavant Company, is a global healthcare technology firm specializing in real-world evidence (RWE) solutions. The company’s Aetion Evidence Platform® utilizes advanced causal inference, rigorous epidemiologic methods, and purpose-built AI to transform complex healthcare data into transparent, reliable evidence regarding the safety, effectiveness, and value of medical treatments. This platform is designed to empower biopharmaceutical companies, medical device manufacturers, payers, and regulatory agencies to make informed decisions throughout the entire product lifecycle, from clinical development and regulatory submissions to market access and post-market assessment.

For physicians, Aetion’s solutions offer a powerful tool to understand how medical innovations perform in real-world settings. By analyzing vast amounts of real-world data, such as electronic health records and claims data, the platform generates scientifically validated insights on what treatments work best, for whom, and when. This evidence can guide product development, optimize clinical trials, and inform treatment and disease landscape understanding. Furthermore, it supports health economics and outcomes research (HEOR) efforts, helping to demonstrate asset value and improve coverage decisions, ultimately aiming to ensure patients receive care that is both clinically effective and cost-efficient.

Focus Areas

Real-world evidence (RWE) solutions causal inference epidemiologic methods AI data analytics drug development market access regulatory submissions post-market safety value-based care synthetic data generation

Business Intelligence

Key Investors	New Enterprise Associates (NEA), Warburg Pincus, Flare Capital Partners, B Capital, Foresite Capital, Greenspring Associates, Lakestar, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, EDBI, Johnson & Johnson Innovation—JJDC, Inc., UCB, Amgen Ventures, Horizon Health Services, Inc., NEC Orchestrating Future Fund
Partnerships	FDA (COVID-19 Research Collaboration, Oncology Center of Excellence), HealthVerity, Prophecy, AWS Marketplace, NEC Orchestrating Future Fund, Intuitive Surgical Inc, xCures
Acquisitions	Acquired by Datavant (May 15, 2025; completed July 11, 2025). Aetion acquired Replica Analytics (January 4, 2022).
Technology	Aetion Evidence Platform® (AEP), a modular, data-agnostic, cloud-native platform (powered by AWS, leveraging Amazon Bedrock for AI/ML). Integrates applications like Aetion® Discover (exploratory analytics), Aetion® Activate (data preparation, hosted coding environment), Aetion® Substantiate (decision-grade descriptive and causal analyses), and Aetion® Generate (AI-driven synthetic health data generation). Employs causal inference, rigorous epidemiologic methods, and transparent audit trails for reproducible, regulatory-grade evidence generation.

What Physicians Need to Know

Real-World Evidence (RWE) Solutions

Aetion specializes in generating decision-grade real-world evidence (RWE) from complex healthcare data using validated epidemiologic methods and causal inference. Their Aetion Evidence Platform (AEP) is a modular, data-agnostic platform that supports RWE generation across clinical, regulatory, and commercial functions.

Causal Inference & Epidemiologic Methods

Aetion's core strength lies in applying advanced causal inference and rigorous epidemiologic methods to transform real-world data into transparent and reliable evidence on the safety, effectiveness, and value of medical treatments.

AI & Data Analytics

The Aetion Evidence Platform leverages AI/ML-driven analytics, including services like Amazon Bedrock, to enhance predictive modeling, patient stratification, and analysis automation. They also have AetionAI, a set of generative AI capabilities embedded across their platform and applications.

Drug Development & Market Access

Aetion's solutions support various stages of drug development, including optimizing clinical trials, creating external control arms, and generating evidence for product labeling. They also assist with market access by demonstrating asset value for payers and health technology assessments (HTA).

Regulatory Submissions & Post-Market Safety

Aetion generates regulatory-grade RWE that complies with global standards, including those set by the FDA and EMA, for regulatory submissions. They also provide solutions for post-market safety and effectiveness assessments.

Synthetic Data Generation

Aetion offers synthetic data generation through their Aetionu00ae Generate application, which uses generative AI to create statistically accurate, privacy-preserved datasets. This enables secure data sharing, expands research opportunities, and improves evidence quality.

Value-Based Care

Aetion's platform helps stakeholders understand what treatments work best, for whom, and when, which is crucial for informing payment models and advancing value-based care.

Physician Tip

For physicians, Aetion's solutions offer the ability to leverage real-world data to understand treatment effectiveness, safety, and value in diverse patient populations, beyond traditional clinical trial settings. This can inform clinical decision-making by providing insights into which treatments are most effective for specific patient profiles and under what circumstances. The transparency and scientific rigor of their RWE can help physicians evaluate treatment options with greater confidence. Furthermore, the platform's ability to generate regulatory-grade evidence means that the insights are robust and reliable, potentially influencing future guidelines and treatment protocols. The integration with Datavant's extensive data network means access to a broader range of real-world patient journeys, offering a more comprehensive view of disease progression and treatment outcomes.

Aetion Evidence Platform is built on a secure, scalable cloud infrastructure powered by AWS. It integrates with Datavant's data exchange network, which connects over 70,000 hospitals and clinics and 300+ real-world data partners, including electronic health records, claims, specialty pharmacy, registries, imaging, labs, and social determinants of health. Aetion also integrates with Databricks for accelerated data ingestion, exploration, and analytics, and offers a secure coding environment like RStudio within its Activate application.

At a glance

Founded 2012

HQ New York, NY, United States · United States

Team size 258

CEO Jeremy Rassen

Funding Acquired (by Datavant) — $212M

Products 1

Visit site

Products by Aetion, a Datavant Company

1 product in the directory

Aetion Evidence

Aetion, a Datavant Company

Drug Discovery & Research

Enterprise

What the Web Says

Aetion, a Datavant Company, is a healthcare technology company specializing in real-world evidence (RWE) solutions for biopharma, payers, and regulatory agencies. The Aetion Evidence Platform is praised for its ability to generate regulatory-grade RWE, transparent analytics, and accelerated time-to-insights. However, employer reviews for its parent company, Datavant, reveal significant concerns regarding frequent organizational changes, inconsistent management, and high workload pressures, particularly in certain operational roles.

Overall: Mixed

Strengths

Generates regulatory-grade real-world evidence (RWE) compliant with FDA and EMA standards.
Provides transparent and reproducible analysis with plain-text audit trails.
Accelerates time-to-insights, potentially reducing study time by up to 50%.
Data-agnostic platform supporting integration of diverse real-world data sources.
Offers AI-driven synthetic data generation and predictive modeling.
Mission-driven work focused on making health data secure, accessible, and actionable.

Limitations

Frequent organizational changes, reorgs, and shifting priorities due to an acquisition-heavy growth strategy.
Inconsistent management quality, with some employees reporting micromanagement and favoritism.
High workload pressure and unattainable productivity metrics in some operational roles.
Low pay and limited opportunities for raises and advancement in certain positions.
Lack of clear guidelines and insufficient training in some departments.
Issues with work-life balance and job security for some employees.

Based on reviews from: Comparably, Zippia, Slashdot, SourceForge, IntuitionLabs.ai, Datavant to Acquire Aetion, Empowering Healthcare and Life Sciences Organizations to Generate High-Quality, Scalable Real-World Evidence from Connected, Privacy-Protected Data, Aetion Revolutionizes Healthcare with Prophecy's AI Data Transformation - YouTube, What Does Aetion Do? | Directory - PromptLoop, What's It Like to Work at Datavant 2026? - Built In, G2, Indeed.com, Reddit, KLAS Research, Breakroom, SimplyHired

Last updated: 2026-09-12

Videos

News, demos, and interviews about Aetion, a Datavant Company.

Loading videos...

Videos load interactively. If none appear, search YouTube for Aetion, a Datavant Company →

View all on YouTube

Press & Coverage

Ardan Equity

Datavant Acquires Aetion

Datavant announced the acquisition of Aetion, a move that expands Datavant's real-world evidence (RWE) capabilities and aims to create an end-to-end offering for data discovery, linkage, privacy, curation, and advanced analysis. This acquisition will combine their ecosystems to over 300 data partners.

2026-05

NPJ Digital Medicine (via PMC)

Crossing borders securely: synthetic data and federated networks for privacy-preserving access to real-world data and emerging use cases

This peer-reviewed article discusses synthetic data and federated data networks as privacy-preserving technologies for accessing real-world data, with a co-author from Aetion, a Datavant Company. It highlights their potential to enable large cohort analysis on diverse populations while ensuring data privacy.

2025-12

Aetion, a Datavant Company

New Release: Aetion Generate 3.7 Enhances Privacy-First Real-World Data Transformation

Aetion announced the release of Aetion Generate 3.7, which focuses on enhancing privacy-first real-world data transformation. This update aims to improve the platform's capabilities for generating regulatory-quality real-world evidence.

2025-05

ISPOR

The Case for Integrated RWE Generation Across the Product Lifecycle

Aetion, a Datavant Company, sponsored a webinar in October 2025 on the case for integrated Real-World Evidence (RWE) generation across the product lifecycle. The webinar aimed to equip health economics and outcomes research (HEOR) and Market Access leaders with arguments for investing in RWD/E.

2025-10

AI Health Index

AI clinical trials companies and software compared | AI Health Index

This article provides an overview of Aetion, a Datavant Company, as a real-world evidence software company. It notes Aetion's founding by Harvard Medical School faculty and its acquisition by Datavant in July 2025, highlighting its focus on pharmaceutical and device sponsors, payers, and regulators.

2026-08

Signalbase

Aetion, a Datavant Company, Secures

Aetion, a Datavant Company, secured $110 million in Series C funding. This funding round was published in May 2021 and is listed among other recent Series C rounds and biggest recent analytics funding rounds.

2021-05

European Stroke Journal

THE IMPACT OF RECURRENT ISCHAEMIC STROKE ON LENGTH OF STAY AND ALL-CAUSE COSTS IN PATIENTS WITH NON-CARDIOEMBOLIC ISCHAEMIC STROKE IN JAPAN: OBSERVATIONS FROM ARISE

This abstract from the European Stroke Journal, published in May 2026, includes authors from Aetion, a Datavant Company, who contributed to research on the impact of recurrent ischemic stroke on healthcare costs and length of stay in Japan.

2026-05

Datavant

Built for Compliance: How Datavant Supports Regulatory-Grade...

This article from Datavant discusses how the company, including Aetion, a Datavant Company, supports regulatory-grade real-world evidence (RWE) generation. It emphasizes privacy and compliance in meeting the intensifying demands of health authorities.

2025-07

Frequently Asked Questions

What is Aetion, a Datavant Company, and how does it leverage Real-World Evidence (RWE) for healthcare decisions?

Aetion, a Datavant Company, is a global healthcare technology company that provides real-world evidence (RWE) solutions to various stakeholders, including biopharmaceutical companies, medical device manufacturers, payers, and regulators. It utilizes the Aetion Evidence Platformu00ae, which applies advanced causal inference, rigorous epidemiologic methods, and purpose-built AI to transform complex healthcare data into transparent, reliable evidence. This evidence helps inform critical healthcare decisions regarding the safety, effectiveness, and value of medical treatments, supporting areas like regulatory submissions, market access, and clinical development.

How does Aetion's platform ensure the scientific rigor and regulatory compliance of its RWE solutions, especially concerning causal inference and epidemiologic methods?

Aetion's platform is purpose-built to enforce regulatory-grade standards throughout the study execution process. It embeds scientific and operational rigor into study workflows, supporting best practices such as protocol locking, controlled access to interim results, and full logging of analytic actions. The platform applies advanced causal inference and rigorous epidemiologic methods, along with AI, to generate transparent, reproducible, and audit-ready evidence that aligns with the most stringent regulatory and scientific expectations, including FDA and EMA guidelines.

What role does AI and data analytics play in Aetion's offerings for drug development, market access, and post-market safety?

Aetion leverages purpose-built AI and advanced data analytics to transform complex healthcare data into reliable evidence. This supports various stages of the drug lifecycle, from optimizing clinical development by speeding time to market and reducing risk, to generating robust evidence for product labeling and post-market safety evaluation. For market access, Aetion helps demonstrate asset value to payers and HTA bodies, improving coverage and accelerating insights. AI also aids in regulatory submissions through advanced data analytics, predictive modeling, and intelligent decision support systems.

What are Aetion's products and solutions, and how do they address the needs of physicians and healthcare administrators?

Aetion offers an end-to-end RWE platform, including products like Aetion Evidence Platformu00ae and Activate. The Aetion Evidence Platformu00ae applies advanced causal inference and AI to generate reliable evidence. Activate is a development solution with low-code tools and a hosted coding environment to help users define measures, transform complex datasets, and execute advanced analytics in a reproducible, audit-ready workflow. These solutions help streamline evidence generation, support regulatory submissions, optimize clinical development, and demonstrate asset value for market access.

How does Aetion, a Datavant Company, address concerns around synthetic data generation, privacy, and compliance?

Aetion, a Datavant Company, offers synthetic data and privacy solutions to help organizations work with sensitive data securely and simplify global compliance. They apply expert determination methodologies to de-identify datasets in line with HIPAA and global privacy standards, and their risk assessment services evaluate data sharing scenarios using advanced statistical models. Synthetic data generation helps protect patient privacy while preserving data utility, enabling secure data sharing, expanding research opportunities, and improving evidence quality.

What is the company's stability and future outlook, especially after becoming 'Aetion, a Datavant Company'?

Datavant acquired Aetion in July 2025, creating an end-to-end RWE platform. This acquisition significantly boosts Datavant's capabilities for life sciences companies and aims to make RWE truly actionable. Datavant is a leading health data platform company with a large ecosystem of data partners, and the combined entity is well-positioned to deliver comprehensive solutions across the healthcare ecosystem. Datavant was projected to see over $1 billion in revenue in 2025 and is profitable and cash-flow positive, indicating strong financial stability.

Related Companies

Suggest an Edit →